Evidence map›Paper›PMID 42382335›Full record

ArticleClinical & translational immunology2026

Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate,

Derrick Neba Nebangwa, Mary Teke Efeti, Sonia M E Momnougui, Cabirou Mounchili Shintouo, Robert Adamu Shey, Rene Bilingwe Ayiseh, Fidele Ntie-Kang, Stephen Mbigha Ghogomu

Abstract read
In one paragraph

Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Derrick Neba NebangwaDepartment of Biochemistry and Molecular Biology, Faculty of Science University of Buea Buea Cameroon.ORCID https://orcid.org/0000-0002-5815-5705
Mary Teke EfetiDepartment of Biochemistry and Molecular Biology, Faculty of Science University of Buea Buea Cameroon.ORCID https://orcid.org/0009-0000-3837-8322
Sonia M E MomnouguiGraduate School of Life Sciences Julius-Maximilians University WÜrzburg WÜrzburg Germany.
Cabirou Mounchili ShintouoDepartment of Microbiology and Immunology, College of Medicine Drexel University Philadelphia Pennsylvania USA.
Robert Adamu SheyDepartment of Biochemistry and Molecular Biology, Faculty of Science University of Buea Buea Cameroon.ORCID https://orcid.org/0000-0003-0146-3894
Rene Bilingwe AyisehDepartment of Biochemistry and Molecular Biology, Faculty of Science University of Buea Buea Cameroon.
Fidele Ntie-KangCenter for Drug Discovery University of Buea Buea Cameroon.
Stephen Mbigha GhogomuDepartment of Biochemistry and Molecular Biology, Faculty of Science University of Buea Buea Cameroon.ORCID https://orcid.org/0000-0003-3459-6554

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Onchocerciasis, caused by the filarial worm Methods: This study investigated the safety and immunogenicity of a novel multi-epitope chimeric antigen, Results: Adjuvanted- Conclusion: These results position

Indexed as

antibody and cellular immune responseBALB/c micechimeric antigenonchocerciasisOvMANE1vaccine

Identifiers

PMID42382335
PMCPMC13317562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.